Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H12N2O |
Molecular Weight | 188.2258 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N(C(=O)C=C1C)C2=CC=CC=C2
InChI
InChIKey=VEQOALNAAJBPNY-UHFFFAOYSA-N
InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
Molecular Formula | C11H12N2O |
Molecular Weight | 188.2258 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Antipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. It is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. It inhibits cyclooxygenases and shows little anti-inflammatory activity. Like many old and approved substances after almost 100 years of use, antipyrine has been associated with some serious side effects, namely agranulocytosis and shock reactions.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 |
|||
Target ID: CHEMBL230 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Finoten Approved UseAntipyrine is indicated for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media; otitis in influenza, the so-called viral bullous otitis; barotraumatic otitis. |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Antipyrine Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The radiological diagnosis of analgesic nephropathy. | 1975 Jul |
|
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. | 2001 |
|
Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule. | 2001 Aug 16 |
|
A female with asymptomatic primary biliary cirrhosis associated with pernicious anemia. | 2001 Dec |
|
Determination of ototoxicity of common otic drops using isolated cochlear outer hair cells. | 2001 Dec |
|
Exercise-induced oxidative stress in older adults as measured by antipyrine oxidation. | 2001 Dec |
|
Derivative ratio spectra-zero crossing spectrophotometry and LC method applied to the quantitative determination of paracetamol, propyphenazone and caffeine in ternary mixtures. | 2001 Dec |
|
Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. | 2001 Feb |
|
Experimental stroke in the female diabetic, db/db, mouse. | 2001 Jan |
|
Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes. | 2001 Jan-Feb |
|
Simultaneous measurement of cerebral blood flow and mRNA signals: pixel-based inter-modality correlational analysis. | 2001 Jul 30 |
|
Synthesis of some triazolyl-antipyrine derivatives and investigation of analgesic activity. | 2001 Jul-Aug |
|
[Effect of hypoxic stress on xenobiotic metabolism and activities of various isoforms of cytochrome P-450]. | 2001 Jul-Aug |
|
Metabolic functions of the liver during chemotherapy in children with acute lymphoblastic leukemia. | 2001 Jun |
|
Oxygen delivery at high blood viscosity and decreased arterial oxygen content to brains of conscious rats. | 2001 Jun |
|
Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine. | 2001 Jun |
|
Urine antipyrine metabolites in rats with different resistance to hypoxia subjected to cold stress. | 2001 Mar |
|
Comparison of cell inactivation by Auger electrons using the two reagents 4-[123I]iodoantipyrine and [123I]NaI. | 2001 Mar |
|
Quantitative analysis of rat inner ear blood flow using the iodo[(14)C]antipyrine technique. | 2001 Mar |
|
Analysis of sialo-N-glycans in glycoproteins as 1-phenyl-3-methyl-5-pyrazolone derivatives by capillary electrophoresis. | 2001 Mar 2 |
|
[The liver monooxygenase system activity in the long-term compression syndrome and treatment with benzonal in prepubertal rats and rabbits]. | 2001 Mar-Apr |
|
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. | 2001 May |
|
In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. | 2001 May 18 |
|
Combined effects of acetaminophen, isopropylantipyrine and caffeine on pregnant and nonpregnant liver. | 2001 Nov |
|
Antioxidant supplementation and exercise-induced oxidative stress in the 60-year-old as measured by antipyrine hydroxylates. | 2001 Nov |
|
Phosphorylation of cyclic adenosine monophosphate response element binding protein in oligodendrocytes in the corpus callosum after focal cerebral ischemia in the rat. | 2001 Oct |
|
Theoretical considerations on the in vivo intestinal permeability determination by means of the single pass and recirculating techniques. | 2001 Oct 23 |
|
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | 2001 Sep |
|
Migraine, Midrin, and Imitrex. | 2002 Apr |
|
The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. | 2002 Apr |
|
The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. | 2002 Apr |
|
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. | 2002 Apr |
|
Synthesis of syn and anti isomers of trans-cyclopropyl arginine. | 2002 Apr 5 |
|
Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. | 2002 Aug |
|
Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats. | 2002 Aug 23 |
|
Exercise-induced oxidative stress in older adults as a function of habitual activity level. | 2002 Feb |
|
Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. | 2002 Feb |
|
Transplacental transfer and metabolism of buprenorphine. | 2002 Jan |
|
Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry. | 2002 Jan |
|
Rational determination of transfer free energies of small drugs across the water-oil interface. | 2002 Jan 3 |
|
Sequential morphological and permeability changes in the rete capillaries during hyperglycaemia. | 2002 Jun 1 |
|
A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. | 2002 Jun 1 |
|
Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. | 2002 Mar |
|
Auto-protective redox buffering systems in stimulated macrophages. | 2002 Mar 12 |
|
Probucol and liver efficiency during chemically-induced hepatocarcinogenesis. | 2002 Mar-Apr |
|
A new method for measuring oxidative stress in claudicants during strenuous exercise using free radical derivatives of antipyrine as indicators: a pilot study. | 2002 Spring |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02037893
54 mg apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping.
Route of Administration:
Otic (auricular)
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7890260
The influence of phenazone on the production of prostacyclin and thromboxane in human umbilical arteries was investigated by in vitro perfusion. With perfusate concentrations ranging from 10(-7) to 10(-4) M a decrease in the formation of both prostanoids was observed. The inhibitory effect of phenazone on prostanoid formation was found to be equal to that of indomethacin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:58:01 GMT 2023
by
admin
on
Fri Dec 15 14:58:01 GMT 2023
|
Record UNII |
T3CHA1B51H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S02DA03
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-ATC |
N02BB71
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-VATC |
QS02DA03
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
5284
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-VATC |
QN02BB01
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-ATC |
N02BB01
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-VATC |
QN02BB51
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-VATC |
QN02BB71
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
||
|
WHO-ATC |
N02BB51
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
31225
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
m1973
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID6021117
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
DB01435
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
T3CHA1B51H
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
D000983
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
1001
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
2206
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
60-80-0
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
T3CHA1B51H
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
861
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
1040005
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL277474
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
413
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
PHENAZONE
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
Antipyrine
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
C76794
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
SUB09753MIG
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
100000085208
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY | |||
|
200-486-6
Created by
admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |